8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Jan 26, 2026·SEC
Milestone Pharmaceuticals Inc.(MIST)Earnings, Financials & Key Ratios
MIST•NASDAQ
Price updated Jun 19, 2026
AboutMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Show more
- Revenue$2M
- EBITDA-$62M-48.5%
- Net Income-$63M-51.9%
- EPS (Diluted)-0.75-11.9%
- Gross Margin92.63%
- EBITDA Margin-4034.35%
- Operating Margin-4041.72%
- Net Margin-4078.78%
- ROE-229.65%+17.3%
MIST Key Insights
Milestone Pharmaceuticals Inc. (MIST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Shares diluted 34.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MIST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MIST Price & Volume
Milestone Pharmaceuticals Inc. (MIST) stock price & volume — 10-year historical chart
Loading chart...
MIST Growth Metrics
Milestone Pharmaceuticals Inc. (MIST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-32.38%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-31.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM13.92%
Return on Capital
10 Years-55.41%
5 Years-65.19%
3 Years-75.56%
Last Year-74.85%
MIST Recent Earnings
Milestone Pharmaceuticals Inc. (MIST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.20-433.3%
$0.06
Rev
$238,000-99.2%
$30M
Q2 2026
Mar 20, 2026Metric
Actual
Est
EPS
$0.16+11.1%
$0.18
Rev
$2M-96.0%
$38M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.12+29.4%
$0.17
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.20-11.1%
$0.18
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.20vs $0.06-433.3% | $238,000vs $30M-99.2% |
| Q2 2026 | Mar 20, 2026 | $0.16vs $0.18+11.1% | $2Mvs $38M-96.0% |
| Q4 2025 | Nov 12, 2025 | $0.12vs $0.17+29.4% | — |
| Q3 2025 | Aug 12, 2025 | $0.20vs $0.18-11.1% | — |
Based on last 12 quarters of dataView full earnings history →
MIST Peer Comparison
Milestone Pharmaceuticals Inc. (MIST) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 XENE | 4.18B | 52.91 | -12.14 | -49.23% | 0.01 | |||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 IDYA | 2.74B | 31.23 | -24.40 | 30.24% | -62.17% | -13.96% | 0.03 | |
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 LXRX | 892.83M | 2.01 | -14.36 | 60.24% | -37.46% | -18.64% | 0.58 | |
 FLGT | 535.45M | 18.00 | -9.14 | 13.83% | -18.75% | -5.42% | 0.00 |
Compare MIST vs Peers
Milestone Pharmaceuticals Inc. (MIST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MIST Income Statement
Milestone Pharmaceuticals Inc. (MIST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 15M | 5M | 1M | 0 | 1.55M | 1.78M |
Revenue Growth % | - | - | - | - | - | -66.67% | -80% | -100% | - | - |
Cost of Goods Sold | 8K | 10K | 0 | 0 | 0 | 0 | 0 | 0 | 114K | 95K |
COGS % of Revenue | - | - | - | - | - | - | - | - | 7.37% | - |
Gross Profit | -8K▲ 0% | -10K▼ 25.0% | 0▲ 100.0% | 0▲ 0% | 15M▲ 0% | 5M▼ 66.7% | 1M▼ 80.0% | 0▼ 100.0% | 1.43M▲ 0% | 1.69M▲ 0% |
Gross Margin % | - | - | - | - | 100% | 100% | 100% | - | 92.63% | 94.67% |
Gross Profit Growth % | - | -25% | 100% | - | - | -66.67% | -80% | -100% | - | - |
Operating Expenses | 8.27M | 23.82M | 57.88M | 50.71M | 58.07M | 64.64M | 62.1M | 42.1M | 63.92M | 67.15M |
OpEx % of Revenue | - | - | - | - | 387.15% | 1292.84% | 6209.8% | - | 4134.35% | - |
Selling, General & Admin | 2.63M | 6.97M | 15.62M | 15.9M | 19.4M | 24.81M | 31.05M | 27.75M | 17.27M | 34.83M |
SG&A % of Revenue | - | - | - | - | 129.35% | 496.26% | 3104.6% | - | 1117.34% | - |
Research & Development | 5.64M | 16.85M | 42.38M | 34.86M | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M | 16.56M |
R&D % of Revenue | - | - | - | - | 257.81% | 796.58% | 3105.2% | - | 1171.28% | - |
Other Operating Expenses | 0 | 0 | -115K | -55K | 0 | 0 | 0 | 0 | 28.54M | 1000K |
Operating Income | -8.27M▲ 0% | -23.82M▼ 188.1% | -57.88M▼ 143.0% | -50.71M▲ 12.4% | -43.07M▲ 15.1% | -59.64M▼ 38.5% | -61.1M▼ 2.4% | -42.1M▲ 31.1% | -62.48M▼ 48.4% | -65.46M▲ 0% |
Operating Margin % | - | - | - | - | -287.15% | -1192.84% | -6109.8% | - | -4041.72% | -3669.39% |
Operating Income Growth % | - | -188.12% | -142.97% | 12.39% | 15.06% | -38.47% | -2.44% | 31.09% | -48.41% | - |
EBITDA | -8.26M | -23.81M | -57.84M | -50.61M | -42.98M | -59.55M | -61.01M | -42M | -62.37M | -65.32M |
EBITDA Margin % | - | - | - | - | -286.53% | -1191.06% | -6100.6% | - | -4034.35% | -3661.38% |
EBITDA Growth % | - | -188.28% | -142.92% | 12.5% | 15.08% | -38.56% | -2.44% | 31.16% | -48.51% | -25.5% |
D&A (Non-Cash Add-back) | 8K | 10K | 38K | 97K | 93K | 89K | 92K | 105K | 114K | 143K |
EBIT | -8.27M | -23.37M | -57.88M | -50.71M | -43.07M | -58.39M | -57.13M | -37.94M | -62.48M | -63.24M |
Net Interest Income | 0 | 0 | 0 | 0 | 220K | 1.25M | 1.41M | 7.75M | -918K | -3.08M |
Interest Income | 186K | 711K | 2.6M | 726K | 220K | 1.25M | 3.97M | 4.16M | 2.92M | 3.96M |
Interest Expense | 0 | 0 | 2.6M | 726K | 0 | 0 | 2.55M | -3.58M | 3.84M | 7.04M |
Other Income/Expense | 186K | 711K | 2.6M | 726K | 220K | 1.25M | 1.41M | 583K | -918K | -3.08M |
Pretax Income | -8.08M▲ 0% | -23.11M▼ 186.0% | 55.28M▲ 339.2% | -49.98M▼ 190.4% | -42.85M▲ 14.3% | -58.39M▼ 36.3% | -59.69M▼ 2.2% | -41.52M▲ 30.4% | -63.4M▼ 52.7% | -68.55M▲ 0% |
Pretax Margin % | - | - | - | - | -285.69% | -1167.76% | -5968.5% | - | -4101.1% | -3842.21% |
Income Tax | 4K | 74K | 56K | -17K | 0 | 0 | 0 | 0 | -345K | -182K |
Effective Tax Rate % | -0.05% | -0.32% | 0.1% | 0.03% | 0% | 0% | 0% | 0% | 0.54% | 0.27% |
Net Income | -8.09M▲ 0% | -23.18M▼ 186.7% | -55.23M▼ 138.2% | -49.97M▲ 9.5% | -42.85M▲ 14.2% | -58.39M▼ 36.3% | -59.69M▼ 2.2% | -41.52M▲ 30.4% | -63.06M▼ 51.9% | -68.36M▲ 0% |
Net Margin % | - | - | - | - | -285.69% | -1167.76% | -5968.5% | - | -4078.78% | -3832.01% |
Net Income Growth % | - | -186.73% | -138.21% | 9.53% | 14.24% | -36.25% | -2.22% | 30.44% | -51.88% | -31.65% |
Net Income (Continuing) | -8.09M | -23.18M | -55.23M | -49.97M | -42.85M | -58.39M | -59.69M | -41.52M | -63.06M | -68.36M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.34▲ 0% | -0.98▼ 188.2% | -3.50▼ 257.1% | -1.70▲ 51.4% | -1.02▲ 40.0% | -1.35▼ 32.4% | -1.39▼ 3.0% | -0.67▲ 51.8% | -0.75▼ 11.9% | -0.52▲ 0% |
EPS Growth % | - | -188.24% | -257.14% | 51.43% | 40% | -32.35% | -2.96% | 51.8% | -11.94% | 13.92% |
EPS (Basic) | -0.34 | -0.98 | -3.50 | -1.70 | -1.02 | -1.35 | -1.39 | -0.67 | -0.75 | - |
Diluted Shares Outstanding | 23.65M | 23.65M | 15.78M | 29.34M | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M | 130.29M |
Basic Shares Outstanding | 23.65M | 23.65M | 15.78M | 29.34M | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M | 130.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MIST Balance Sheet
Milestone Pharmaceuticals Inc. (MIST) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 27.55M | 88.05M | 122.5M | 148.69M | 118.92M | 71.8M | 73.03M | 73.93M | 111.92M | 192.25M |
Cash & Short-Term Investments | 26.91M | 85.98M | 119.82M | 142.31M | 114.14M | 64.58M | 66M | 69.69M | 105.96M | 184.22M |
Cash Only | 10.88M | 85.95M | 119.82M | 72.31M | 114.14M | 7.64M | 13.76M | 25.31M | 73.05M | 71.32M |
Short-Term Investments | 16.03M | 29K | 0 | 70M | 0 | 56.95M | 52.24M | 44.38M | 32.91M | 112.9M |
Accounts Receivable | 543K | 677K | 0 | 0 | 483K | 1.21M | 3.85M | 2.39M | 3.51M | 5M |
Days Sales Outstanding | - | - | - | - | 11.75 | 88.55 | 1.41K | - | 828.21 | 614.81 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 648K | 1.83M |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | 2.07K | 2.38K |
Other Current Assets | 0 | 0 | 836K | 948K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 35K | 30K | 929K | 1.29M | 926K | 2.68M | 2.19M | 1.57M | 1.64M | 1.48M |
Property, Plant & Equipment | 35K | 30K | 929K | 1.29M | 926K | 2.68M | 2.19M | 1.57M | 1.64M | 1.48M |
Fixed Asset Turnover | - | - | - | - | 16.20x | 1.87x | 0.46x | - | 0.94x | 1.31x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 27.59M▲ 0% | 88.08M▲ 219.2% | 123.43M▲ 40.1% | 149.97M▲ 21.5% | 119.85M▼ 20.1% | 74.48M▼ 37.9% | 75.23M▲ 1.0% | 75.5M▲ 0.4% | 113.56M▲ 50.4% | 193.73M▲ 0% |
Asset Turnover | - | - | - | - | 0.13x | 0.07x | 0.01x | - | 0.01x | 0.02x |
Asset Growth % | - | 219.25% | 40.13% | 21.51% | -20.09% | -37.85% | 1% | 0.36% | 50.41% | 222.71% |
Total Current Liabilities | 1.6M | 4.53M | 8.33M | 6.16M | 6.78M | 6.14M | 7.23M | 8.13M | 13.98M | 20.94M |
Accounts Payable | 4K | 2.6M | 4.38M | 4.64M | 4.38M | 2.26M | 3.98M | 1.93M | 5.64M | 10.02M |
Days Payables Outstanding | 182.5 | 95.01K | - | - | - | - | - | - | 18.07K | 20.92K |
Short-Term Debt | 0 | 0 | 0 | 0 | 224K | 495K | 0 | 0 | 647K | 659K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 416K |
Other Current Liabilities | 1.11M | 56K | 0 | 0 | 709K | 808K | 1.99M | 0 | 7.69M | 8.69M |
Current Ratio | 17.17x | 19.42x | 14.71x | 24.14x | 17.55x | 11.70x | 10.11x | 9.10x | 8.01x | 9.18x |
Quick Ratio | 17.17x | 19.42x | 14.71x | 24.14x | 17.55x | 11.70x | 10.11x | 9.10x | 7.96x | 9.09x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -15.17K | -17.93K |
Total Non-Current Liabilities | 59.1M | 138.76M | 184K | 696K | 474K | 2M | 51.23M | 54.23M | 57.81M | 136.74M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 49.77M | 53.35M | 57.19M | 136.3M |
Capital Lease Obligations | 0 | 0 | 184K | 696K | 474K | 2M | 1.46M | 874K | 539K | 2.06M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 59.1M | 138.76M | 0 | 0 | 0 | 0 | 0 | 0 | 83K | 72K |
Total Liabilities | 60.71M | 143.29M | 8.51M | 6.86M | 7.25M | 8.13M | 58.45M | 62.35M | 71.79M | 157.69M |
Total Debt | 0 | 0 | 514K | 941K | 698K | 2.49M | 51.77M | 54.8M | 58.38M | 137.33M |
Net Debt | -10.88M | -85.95M | -119.3M | -71.37M | -113.44M | -5.14M | 38.02M | 29.48M | -14.67M | 66.01M |
Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.04x | 3.09x | 4.17x | 1.40x | 3.81x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.10x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.01x |
Interest Coverage | - | - | -22.30x | -69.85x | - | - | -22.37x | -10.59x | -16.28x | -8.99x |
Total Equity | -33.12M▲ 0% | -55.21M▼ 66.7% | 114.92M▲ 308.1% | 143.12M▲ 24.5% | 112.6M▼ 21.3% | 66.35M▼ 41.1% | 16.77M▼ 74.7% | 13.15M▼ 21.6% | 41.77M▲ 217.7% | 36.05M▲ 0% |
Equity Growth % | - | -66.7% | 308.15% | 24.54% | -21.32% | -41.08% | -74.72% | -21.61% | 217.71% | 736.34% |
Book Value per Share | -1.40 | -2.33 | 7.28 | 4.88 | 2.69 | 1.56 | 0.39 | 0.21 | 0.50 | 0.28 |
Total Shareholders' Equity | -33.12M | -55.21M | 114.92M | 143.12M | 112.6M | 66.35M | 16.77M | 13.15M | 41.77M | 36.05M |
Common Stock | 1.23M | 2.04M | 226.25M | 251.68M | 251.9M | 273.9M | 260.5M | 288.05M | 352.62M | 373.7M |
Retained Earnings | -35.09M | -58.27M | -113.5M | -163.47M | -206.32M | -266.34M | -326.03M | -367.55M | -430.6M | -456.67M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.63M | -1.63M | -1.63M | 46.37M | 51.31M | 34.35M | 48.46M | 53.08M | 55.65M | 55.65M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MIST Cash Flow Statement
Milestone Pharmaceuticals Inc. (MIST) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.05M | -21.05M | -51.15M | -50.73M | -33.22M | -52.47M | -46.42M | -28.85M | -49.04M | -51.21M |
Operating CF Margin % | - | - | - | - | -221.49% | -1049.38% | -4642.4% | - | -3172.12% | - |
Operating CF Growth % | - | -161.38% | -143.05% | 0.82% | 34.51% | -57.93% | 11.52% | 37.86% | -70% | -249.21% |
Net Income | -8.09M | -23.18M | -55.23M | -49.97M | -42.85M | -58.39M | -59.69M | -41.52M | -63.06M | -68.36M |
Depreciation & Amortization | 8K | 10K | 38K | 97K | 93K | 89K | 92K | 105K | 114K | 143K |
Stock-Based Compensation | 190K | 633K | 1.19M | 4.95M | 7.28M | 9.05M | 9.53M | 5.78M | 7.46M | 6.14M |
Deferred Taxes | 0 | 0 | -1.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 59K | 787K | 1.63M | 0 | 0 | 44K | 2.39M | 3.13M | 3.76M | 8.26M |
Working Capital Changes | -164K | 1.5M | 2.85M | -5.81M | 2.26M | -3.26M | 1.24M | 3.66M | 2.68M | 2.6M |
Change in Receivables | 147K | -134K | -169K | -112K | 465K | -730K | -2.64M | 1.46M | -1.12M | -2.85M |
Change in Inventory | 0 | 0 | 169K | 0 | 0 | 0 | 0 | 0 | -648K | -1.18M |
Change in Payables | -222K | 2.88M | 3.52M | -2.08M | 0 | 0 | 0 | 0 | 4.43M | 7.58M |
Cash from Investing | -16.02M | 16M | -384K | -70M | 70M | -57.12M | 4.76M | 8.28M | 11.25M | -103.03M |
Capital Expenditures | -36K | -5K | -413K | 0 | 0 | -272K | -112K | -33K | -302K | -74.98K |
CapEx % of Revenue | - | - | - | - | - | 5.44% | 11.2% | - | 19.53% | 4.2% |
Acquisitions | 0 | 0 | 35.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -15.99M | 16M | -35.41M | 0 | 0 | 0 | 0 | 0 | 0 | -46.36M |
Cash from Financing | 30.72M | 80.11M | 85.41M | 73.22M | 5.05M | 3.09M | 47.79M | 32.12M | 85.53M | 180.48M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 50M | 0 | 0 | 75M |
Equity Issued (Net) | 31M | 79.65M | 85.36M | 24.92M | 0 | 2.63M | 0 | 27.26M | 85.53M | 104.89M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -278K | 461K | 44K | 48.31M | 5.05M | 458K | -2.21M | 4.86M | 0 | 599.2K |
Net Change in Cash | 6.65M▲ 0% | 75.07M▲ 1029.3% | 33.87M▼ 54.9% | -47.51M▼ 240.3% | 41.83M▲ 188.1% | -106.5M▼ 354.6% | 6.12M▲ 105.7% | 11.55M▲ 88.7% | 47.73M▲ 313.1% | 26.23M▲ 0% |
Free Cash Flow | -8.09M▲ 0% | -21.05M▼ 160.3% | -51.56M▼ 145.0% | -50.73M▲ 1.6% | -33.22M▲ 34.5% | -52.74M▼ 58.7% | -46.54M▲ 11.8% | -28.88M▲ 37.9% | -49.34M▼ 70.8% | -51.23M▲ 0% |
FCF Margin % | - | - | - | - | -221.49% | -1054.82% | -4653.6% | - | -3191.66% | -2871.85% |
FCF Growth % | - | -160.27% | -144.95% | 1.62% | 34.51% | -58.74% | 11.77% | 37.94% | -70.85% | -51.11% |
FCF per Share | -0.34 | -0.89 | -3.27 | -1.73 | -0.79 | -1.24 | -1.08 | -0.46 | -0.59 | -0.39 |
FCF Conversion (FCF/Net Income) | 1.00x | 0.91x | 0.93x | 1.02x | 0.78x | 0.90x | 0.78x | 0.69x | 0.78x | 0.75x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MIST Key Ratios
Milestone Pharmaceuticals Inc. (MIST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -185% | -38.73% | -33.52% | -65.26% | -143.61% | -277.55% | -229.65% | -339.38% |
Return on Invested Capital (ROIC) | - | - | -112.92% | -91.12% | -148.22% | -79.01% | -64.83% | -134.41% | -125.62% |
Gross Margin | - | - | - | 100% | 100% | 100% | - | 92.63% | 94.67% |
Net Margin | - | - | - | -285.69% | -1167.76% | -5968.5% | - | -4078.78% | -3832.01% |
Debt / Equity | - | 0.00x | 0.01x | 0.01x | 0.04x | 3.09x | 4.17x | 1.40x | 3.81x |
Interest Coverage | - | -22.30x | -69.85x | - | - | -22.37x | -10.59x | -16.28x | -8.99x |
FCF Conversion | 0.91x | 0.93x | 1.02x | 0.78x | 0.90x | 0.78x | 0.69x | 0.78x | 0.75x |
Revenue Growth | - | - | - | - | -66.67% | -80% | -100% | - | - |
Related:MIST Dividend History·MIST Revenue History·MIST Price History·MIST P/E History·MIST Financial Ratios·MIST Institutional Holders
MIST SEC Filings & Documents
Milestone Pharmaceuticals Inc. (MIST) SEC filings — annual & quarterly reports (10-K, 10-Q)
MIST Frequently Asked Questions
Milestone Pharmaceuticals Inc. (MIST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Milestone Pharmaceuticals Inc. (MIST) reported $1.8M in revenue for fiscal year 2025.
Milestone Pharmaceuticals Inc. (MIST) grew revenue by 0.0% over the past year. Growth has been modest.
Milestone Pharmaceuticals Inc. (MIST) reported a net loss of $68.4M for fiscal year 2025.
Dividend & Returns
Milestone Pharmaceuticals Inc. (MIST) has a return on equity (ROE) of -229.7%. Negative ROE indicates the company is unprofitable.
Milestone Pharmaceuticals Inc. (MIST) had negative free cash flow of $51.2M in fiscal year 2025, likely due to heavy capital investments.